DAX19.849 -0,2%ESt504.866 +0,3%Top 10 Crypto14,68 -3,3%Dow42.907 +0,2%Nas19.765 +1,0%Bitcoin90.418 -0,6%Euro1,0402 ±-0,0%Öl73,30 +0,5%Gold2.614 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T Novo Nordisk A3EU6F Volkswagen (VW) vz. 766403 Palantir A2QA4J Rheinmetall 703000 MicroStrategy 722713 Apple 865985 Amazon 906866 Bayer BAY001 Mercedes-Benz Group (ex Daimler) 710000 Siemens Energy ENER6Y Allianz 840400 TUI TUAG50 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Ruhiger Wochenauftakt: DAX letztlich im Minus -- VW: Einigung im Tarifkonflikt -- BMW: Unregelmäßigkeiten bei Autoexporten -- Mercedes-Benz, BVB, AstraZeneca im Fokus
Top News
Zuversicht in London: FTSE 100 mit positivem Vorzeichen Zuversicht in London: FTSE 100 mit positivem Vorzeichen
Optimismus in Paris: CAC 40 liegt am Mittag im Plus Optimismus in Paris: CAC 40 liegt am Mittag im Plus
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AstraZeneca Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
126,30 EUR +1,75 EUR +1,41 %
XETRA
104,58 GBP +0,36 GBP +0,35 %
LSE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.194,86 Mrd. EUR

KGV34,27Div. Rendite2,15%

WKN886455

ISINGB0009895292

SymbolAZNCF

AstraZeneca Aktien News

DatumMeistgelesen
PR NewswireAllorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
PR NewswireAllorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
PR NewswireAllorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
PR NewswireAllorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
BenzingaChina Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
ZacksAstrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
ZacksAstrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
BenzingaRecent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
ZacksAstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
ZacksAstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
BenzingaEvaluating AstraZeneca Against Peers In Pharmaceuticals Industry
BenzingaHealth Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies
Financial TimesAstraZeneca set to make one of its first acquisitions in China
BenzingaAstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
Business TimesAstraZeneca to buy China-based Gracell Biotechnologies in US$1.2 billion deal
MarketWatchIonis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
PR NewswireCompugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
PR NewswireKoselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas
PR NewswirePresage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
PR NewswireHealth Canada approves Ultomiris for adults with neuromyelitis optica spectrum disorder (NMOSD)
PR NewswireHealth Canada approves Ultomiris for adults with neuromyelitis optica spectrum disorder (NMOSD)
PR NewswireAlexion, AstraZeneca Rare Disease, concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of patients with paroxysmal nocturnal hemog...
PR NewswireAlexion, AstraZeneca Rare Disease, concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of patients with paroxysmal nocturnal hemog...
PR NewswireSOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
PR NewswireSOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
PR NewswireSOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
PR NewswireSOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
PR NewswireFusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
PR NewswireFusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
PR NewswireASTRAZENECA AND INSTITUT KANSER NEGARA PARTNER TO INTRODUCE AI TECHNOLOGY FOR LUNG SCREENING
PR NewswireShanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
PR NewswireShanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
PR NewswireShanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
PR NewswireShanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
PR NewswireNew analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy
PR NewswireFusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy
PR NewswireFusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy
PR NewswireAstraZeneca Thailand Wins Two ACES Awards 2022: "Industry Champions of the Year" and "Community Initiative"
PR NewswireInvitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
PR NewswireHONEYWELL BEGINS PRODUCTION OF NEAR-ZERO GLOBAL-WARMING-POTENTIAL MEDICAL PROPELLANT

AstraZeneca News

AstraZeneca News: auf dieser Seite finden Sie alle AstraZeneca News und Nachrichten zur AstraZeneca Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AstraZeneca News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AstraZeneca News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.